Imaging of dopaminergic transmission in
neurodegenerative disorders such as
Parkinson disease (PD) or
dementia with Lewy bodies plays a major role in clinical practice and in clinical research. We here review the role of imaging of the nigrostriatal pathway, as well as of striatal receptors and
dopamine release, in common
neurodegenerative disorders in clinical practice and research. Imaging of the nigrostriatal pathway has a high diagnostic accuracy to detect nigrostriatal degeneration in disorders characterized by nigrostriatal degeneration, such as PD and
dementia with Lewy bodies, and disorders of more clinical importance, namely in patients with clinically uncertain
parkinsonism. Imaging of striatal
dopamine D2/3 receptors is not recommended for the differential diagnosis of
parkinsonian disorders in clinical practice anymore. Regarding research, recently the European Medicines Agency has qualified
dopamine transporter imaging as an enrichment
biomarker for clinical trials in early PD, which underlines the high diagnostic accuracy of this imaging tool and will be implemented in future trials. Also, imaging of the presynaptic dopaminergic system plays a major role in, for example, examining the extent of nigrostriatal degeneration in preclinical and premotor phases of
neurodegenerative disorders and to examine subtypes of PD. Also, imaging of postsynaptic
dopamine D2/3 receptors plays a role in studying, for example, the neuronal substrate of
impulse control disorders in PD, as well as in measuring endogenous
dopamine release to examine, for example, motor complications in the treatment of PD. Finally, novel MRI sequences as
neuromelanin-sensitive MRI are promising new tools to study nigrostriatal degeneration in vivo.